Platelet rich plasma in xeno-free stem cell culture: the impact of platelet count and processing method.
Pawitan JA.
Animal Study, published in Curr Stem Cell Res Ther (2012) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Curr Stem Cell Res Ther (2012)
- Country
- United Arab Emirates
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 22849700
- DOI
- 10.2174/157488812802481508
Abstract (original English)
Stem cell culture for regenerative medicine needs platelet rich plasma (PRP) as fetal bovine/calf serum (FBS/FCS) substitute. However, the various studies used various protocols in preparing and processing the PRP. This study aimed to compare and conclude the most effective and efficient protocol. we searched in vitro studies that used human PRP as FBS/FCS substitute to culture human cells, and compared the various available protocols to identify the easiest and effective protocols for the preparation of PRP and the release of the growth factors (GFs) to support the highest cell growth in stem cell culture. ten studies fulfilled the selection criteria and were included in the analysis. Almost all studies on bone marrow mesenchymal stem cell (BM-MSC) and adipose stem cell (AT-SC) showed that platelet lysate and/or activated platelet releasate were superior or at least the same as either FBS or FCS, except for one study that got different results on human AT-SC. Several studies showed that either 5% activated PRP (aPRP) or platelet lysate (PL) was sufficient to support cell growth, or even better when they were compared to 10% FBS, while higher concentrations were counterproductive. However, some studies showed that 10% aPRP or PL was needed. The difference between studies was due to the difference in either the PRP preparation from blood and in the PRP processing to release the
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.